These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1224 related articles for article (PubMed ID: 29067721)

  • 41. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.
    Zuo Y; Xiao H; Lv D; Huang M; Wang L; Liu J; Zhang K; Shen J; Wang Z; Wu Q; Xu Y
    J Med Virol; 2023 Apr; 95(4):e28717. PubMed ID: 37184049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
    Noh BJ; Kim JH; Eom DW
    Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
    Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
    J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
    Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
    Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
    J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
    Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
    PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.